Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study
Zhiwei Chen,1,* Shengping Shen,1,* Wenbo Shi,1,* Gening Jiang,2 Xin Wang,3 Hong Jian,1 Zhen Zhou,1 Zhengping Ding,1 Shun Lu11Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, People’s Republic of China; 2Department of Thoracic Surgery,...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-07-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/intercalated-combination-of-chemotherapy-and-erlotinib-for-stage-iiia--peer-reviewed-article-CMAR |
id |
doaj-16be64341e1346cd98301b0734fd0729 |
---|---|
record_format |
Article |
spelling |
doaj-16be64341e1346cd98301b0734fd07292020-11-25T01:15:06ZengDove Medical PressCancer Management and Research1179-13222019-07-01Volume 116543655247096Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II studyChen ZShen SShi WJiang GWang XJian HZhou ZDing ZLu SZhiwei Chen,1,* Shengping Shen,1,* Wenbo Shi,1,* Gening Jiang,2 Xin Wang,3 Hong Jian,1 Zhen Zhou,1 Zhengping Ding,1 Shun Lu11Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, People’s Republic of China; 2Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, People’s Republic of China; 3Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China*These authors contributed equally to this workObjective: This multicenter, open-label, single-arm, phase II trial evaluated the efficacy and safety of an intercalated combination of erlotinib and gemcitabine/cisplatin or carboplatin in patients with stage IIIA non-small-cell lung cancer (NSCLC).Registration: This trial is registered with ClinicalTrials.gov, number NCT01297101.Methods: The primary endpoint was the objective response rate (ORR), which includes complete response (CR) and partial response (PR), assessed using RECIST version 1.0 in the intention-to-treat population. Adverse events (AEs) were graded by the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Secondary endpoints included the disease control rate, disease-free survival (DFS), overall survival (OS), and safety. Between April 1, 2011, and July 31, 2014, 39 patients with stage IIIA NSCLC received two cycles of intercalated use of erlotinib with gemcitabine/cisplatin or carboplatin.Results: Eighteen patients (46.15%) achieved a PR and no patient achieved a pathologic CR, resulting in an ORR of 46.15% (95% CI 30–63%). Median DFS was 20 months (95% CI 5.26–50.61) and median OS was 25 months (95% CI 15.57–33.39). Patients with EGFR mutations (n=7) had a higher ORR than those with wild-type EGFR (n=9) (85.71% vs 55.56%, P=0.00). Most AEs were CTCAE grade 1 or 2; there were no cases of increased hematologic toxicity or erlotinib-emergent interstitial lung disease observed.Conclusion: Two cycles of intercalated neoadjuvant therapy with erlotinib and gemcitabine/cisplatin or carboplatin were effective and safe for patients with stage IIIA NSCLC. This approach should be further explored in larger randomized controlled trials given the lack of a consensus about the best treatment for stage IIIA NSCLC.Keywords: non-small-cell lung cancer, NSCLC, neoadjuvant, erlotinib, gemcitabine, platinum, objective response rate, progression-free survival, overall survivalhttps://www.dovepress.com/intercalated-combination-of-chemotherapy-and-erlotinib-for-stage-iiia--peer-reviewed-article-CMARnon-small cell lung cancer (NSCLC)neoadjuvanterlotinibgemcitabineplatinumobjective response rateprogression-free survivaloverall survival |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Chen Z Shen S Shi W Jiang G Wang X Jian H Zhou Z Ding Z Lu S |
spellingShingle |
Chen Z Shen S Shi W Jiang G Wang X Jian H Zhou Z Ding Z Lu S Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study Cancer Management and Research non-small cell lung cancer (NSCLC) neoadjuvant erlotinib gemcitabine platinum objective response rate progression-free survival overall survival |
author_facet |
Chen Z Shen S Shi W Jiang G Wang X Jian H Zhou Z Ding Z Lu S |
author_sort |
Chen Z |
title |
Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study |
title_short |
Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study |
title_full |
Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study |
title_fullStr |
Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study |
title_full_unstemmed |
Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study |
title_sort |
intercalated combination of chemotherapy and erlotinib for stage iiia non-small-cell lung cancer: a multicenter, open-label, single-arm, phase ii study |
publisher |
Dove Medical Press |
series |
Cancer Management and Research |
issn |
1179-1322 |
publishDate |
2019-07-01 |
description |
Zhiwei Chen,1,* Shengping Shen,1,* Wenbo Shi,1,* Gening Jiang,2 Xin Wang,3 Hong Jian,1 Zhen Zhou,1 Zhengping Ding,1 Shun Lu11Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, People’s Republic of China; 2Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, People’s Republic of China; 3Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China*These authors contributed equally to this workObjective: This multicenter, open-label, single-arm, phase II trial evaluated the efficacy and safety of an intercalated combination of erlotinib and gemcitabine/cisplatin or carboplatin in patients with stage IIIA non-small-cell lung cancer (NSCLC).Registration: This trial is registered with ClinicalTrials.gov, number NCT01297101.Methods: The primary endpoint was the objective response rate (ORR), which includes complete response (CR) and partial response (PR), assessed using RECIST version 1.0 in the intention-to-treat population. Adverse events (AEs) were graded by the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Secondary endpoints included the disease control rate, disease-free survival (DFS), overall survival (OS), and safety. Between April 1, 2011, and July 31, 2014, 39 patients with stage IIIA NSCLC received two cycles of intercalated use of erlotinib with gemcitabine/cisplatin or carboplatin.Results: Eighteen patients (46.15%) achieved a PR and no patient achieved a pathologic CR, resulting in an ORR of 46.15% (95% CI 30–63%). Median DFS was 20 months (95% CI 5.26–50.61) and median OS was 25 months (95% CI 15.57–33.39). Patients with EGFR mutations (n=7) had a higher ORR than those with wild-type EGFR (n=9) (85.71% vs 55.56%, P=0.00). Most AEs were CTCAE grade 1 or 2; there were no cases of increased hematologic toxicity or erlotinib-emergent interstitial lung disease observed.Conclusion: Two cycles of intercalated neoadjuvant therapy with erlotinib and gemcitabine/cisplatin or carboplatin were effective and safe for patients with stage IIIA NSCLC. This approach should be further explored in larger randomized controlled trials given the lack of a consensus about the best treatment for stage IIIA NSCLC.Keywords: non-small-cell lung cancer, NSCLC, neoadjuvant, erlotinib, gemcitabine, platinum, objective response rate, progression-free survival, overall survival |
topic |
non-small cell lung cancer (NSCLC) neoadjuvant erlotinib gemcitabine platinum objective response rate progression-free survival overall survival |
url |
https://www.dovepress.com/intercalated-combination-of-chemotherapy-and-erlotinib-for-stage-iiia--peer-reviewed-article-CMAR |
work_keys_str_mv |
AT chenz intercalatedcombinationofchemotherapyanderlotinibforstageiiianonsmallcelllungcanceramulticenteropenlabelsinglearmphaseiistudy AT shens intercalatedcombinationofchemotherapyanderlotinibforstageiiianonsmallcelllungcanceramulticenteropenlabelsinglearmphaseiistudy AT shiw intercalatedcombinationofchemotherapyanderlotinibforstageiiianonsmallcelllungcanceramulticenteropenlabelsinglearmphaseiistudy AT jiangg intercalatedcombinationofchemotherapyanderlotinibforstageiiianonsmallcelllungcanceramulticenteropenlabelsinglearmphaseiistudy AT wangx intercalatedcombinationofchemotherapyanderlotinibforstageiiianonsmallcelllungcanceramulticenteropenlabelsinglearmphaseiistudy AT jianh intercalatedcombinationofchemotherapyanderlotinibforstageiiianonsmallcelllungcanceramulticenteropenlabelsinglearmphaseiistudy AT zhouz intercalatedcombinationofchemotherapyanderlotinibforstageiiianonsmallcelllungcanceramulticenteropenlabelsinglearmphaseiistudy AT dingz intercalatedcombinationofchemotherapyanderlotinibforstageiiianonsmallcelllungcanceramulticenteropenlabelsinglearmphaseiistudy AT lus intercalatedcombinationofchemotherapyanderlotinibforstageiiianonsmallcelllungcanceramulticenteropenlabelsinglearmphaseiistudy |
_version_ |
1725154390664282112 |